- Home
- ATNM
as of 03-24-2026 3:17pm EST
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 36.8M | IPO Year: | 2013 |
| Target Price: | $4.00 | AVG Volume (30 days): | 98.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.90 | EPS Growth: | 30.60 |
| 52 Week Low/High: | $1.02 - $1.95 | Next Earning Date: | 05-08-2026 |
| Revenue: | $81,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.22 | Index: | N/A |
| Free Cash Flow: | -33083000.0 | FCF Growth: | N/A |
Earnings Transcripts
SEC 8-K filings with transcript text
2015 Q2 Q2 2015 Earnings
8-K Aug 3, 2015
Q2 2015 Earnings
8-KAug 3, 2015
8-K 1 f8k072915_actiniumpharmac.htm
CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 29, 2015
ACTINIUM PHARMACEUTICALS,
INC.
(Exact name of registrant as specified in its charter)
Delaware
000-52446
74-2963609
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
757 Third Avenue, 21st Floor New York, NY
10017
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (646) 459-4201
546 Fifth Avenue, 14th Floor, NY, NY 10036
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 2.02. Results of Operations and Financial Condition.
In a letter to shareholders, dated July 29, 2015, Actinium Pharmaceuticals, Inc. (the “Company”) reported that its pro forma cash position at June 30, 2015 was approximately $27 million. A copy of the shareholder letter is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 2.02 by reference.
Item 7.01. Regulation FD Disclosure.
A copy of a shareholder letter mailed to Company shareholders on July 29, 2015 is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.
The response to Item 2.02 is incorporated herein by reference to this Item 7.01.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
Exhibit Number
Description
99.1
Letter to Shareholders, dated July 29, 2015
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ACTINIUM PHARMACEUTICALS, INC.
Dated: August 3, 2015 By: /s/ Kaushik J. Dave
Name: Kaushik J. Dave
Title: President and Chief Executive Officer
3
Compare ATNM vs Leading Stocks
See how ATNM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ATNM Actinium Pharmaceuticals Inc. (Delaware) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.